This is a phase I/II, single-arm, open-lable study of autologous stem cell transplantation in combination with C-CAR088, an autologous BCMA CAR-T cell product, for patients with ulta high-risk multiple myeloma, defined as failed or unsatisfied responses to front line VRD-based treatment with or without the presence of multiple high-risk cytogenetic features.
Transplantation eligible patients, male or female, aged 18 to 70 years
Ultra high risk multiple myeloma, defined as failed or unsatisfied responses to front line VRD-based treatment with or without the presence of multiple high-risk cytogenetic features
Adequate liver, renal, bone marrow, and heart function
Eastern Cooperative Oncology Group (ECOG) Performance status 0-1.
Known allergies to the components or excipients of the C-CAR088 cell product
Prior allogenic HSCT, or ASCT
CNS involvement
Stroke or convulsion history within 6 months prior to signing ICF
Institute of Hematology & Blood Diseases Hospital, China
Lead sponsor
Shanghai AbelZeta Ltd.
Collaborator